SCHEMBL1224249

SCHEMBL1224249

COc1ccc2nccc(N3CC(C(N)=O)C3)c2n1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 2/20 0.49
EHMT1 Q9H9B1 2/20 0.49
CYP8B1 Q9UNU6 1/20 0.45
KMT2A Q03164 1/20 0.38
KCNH2 Q12809 7/20 0.38
PBK Q96KB5 1/20 0.37
PIK3CA P42336 2/20 0.37
PIK3CD O00329 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
HCRTR1 O43613 2/20 0.35
HCRTR2 O43614 2/20 0.35
NNMT P40261 1/20 0.35
CYP2C19 P33261 1/20 0.35
EIF2AK4 Q9P2K8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668757 0.91 CYP8B1 (0.51) EHMT2EHMT1CYP8B1KMT2AKCNH2
SCHEMBL3667650 0.91 CYP8B1 (0.51) EHMT2EHMT1CYP8B1KMT2AKCNH2
SCHEMBL3665597 0.91 CYP8B1 (0.51) EHMT2EHMT1CYP8B1KMT2AKCNH2
SCHEMBL3630741 0.89 EHMT2 (0.48) EHMT2EHMT1CYP8B1KCNH2PIK3CA
SCHEMBL1224035 0.84 CYP2C19 (0.43) CYP8B1KCNH2PIK3CACYP2C19
SCHEMBL10078646 0.83 CYP8B1 (0.53) EHMT2EHMT1CYP8B1KCNH2PIK3CA
SCHEMBL1224565 0.83 CYP8B1 (0.53) EHMT2EHMT1CYP8B1KCNH2PIK3CA
SCHEMBL3665484 0.83 CYP8B1 (0.53) EHMT2EHMT1CYP8B1KCNH2PIK3CA
SCHEMBL1224184 0.82 CYP8B1 (0.41) EHMT2EHMT1CYP8B1KCNH2PIK3CA
SCHEMBL1224187 0.82 CYP8B1 (0.41) EHMT2EHMT1CYP8B1KCNH2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2144910-B1 OXAZOLIDINONE ANTIBIOTICS ACTELION PHARMACEUTICALS LTD (CH) 2015-10-28 EP claimed
US-8217029-B2 Oxazolidinone antibiotics ACTELION PHARMACEUTICALS LTD (CH) 2012-07-10 US claimed
EP-2915813-B1 Oxazolidinone antibiotics ACTELION PHARMACEUTICALS LTD (CH) 2017-02-01 EP disclosed
EP-2144910-B1 OXAZOLIDINONE ANTIBIOTICS ACTELION PHARMACEUTICALS LTD (CH) 2015-10-28 EP disclosed
EP-2915813-A1 Oxazolidinone antibiotics Actelion Pharmaceuticals Ltd. (CH) 2015-09-09 EP disclosed
EP-2905283-A1 Oxazolidinone antibiotics Actelion Pharmaceuticals Ltd. (CH) 2015-08-12 EP disclosed
US-8217029-B2 Oxazolidinone antibiotics ACTELION PHARMACEUTICALS LTD (CH) 2012-07-10 US disclosed
US-20110039823-A1 OXAZOLIDINONE ANTIBIOTICS ACTELION PHARMACEUTICALS LTD (CH) 2011-02-17 US disclosed
EP-2144910-A2 OXAZOLIDINONE ANTIBIOTICS Actelion Pharmaceuticals Ltd. (CH) 2010-01-20 EP disclosed
WO-2008126034-A2 OXAZOLIDINONE ANTIBIOTICS ACTELION PHARMACEUTICALS LTD (CH) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039823-A1 OXAZOLIDINONE ANTIBIOTICS OXA1L, XDH, UBE2D3 EHMT2 4429/4885EHMT1 3766/4885CYP8B1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.